Clinical Trials Browser

Nasopharyngeal Neoplasms

NCT05011227 2024-03-06

Camrelizumab and Chemotherapy Combined With Endoscopic Surgery for Recurrent Nasopharyngeal Carcinoma

Phase 2 Unknown

100 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT06170697 2023-12-20

Advanced First-line Treatment of Short-term Postoperative Progression of Head and Neck Squamous Cell Carcinoma

Phase 2 Unknown

46 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT05576272 2023-11-22

A Phase II/III Trial to Evaluate the Efficacy and Safety of QL1706 in Patients With Nasopharyngeal Carcinoma

Phase 2/3 Unknown

460 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT04156698 2023-08-09

Induction Chemotherapy Combined With Immunotherapy for Locally Advanced Hypopharyngeal Carcinoma

Phase 2 Unknown

51 enrolled

Head & Neck

Hypopharyngeal Neoplasms

NCT04221516 2023-06-18

Camrelizumab After Completion of Radiotherapy for Oligometastatic Nasopharyngeal Carcinoma

Phase 2 Unknown

52 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT04586088 2023-05-06

Apatinib and Camrelizumab in Recurrent or Metastatic Nasopharyngeal Carcinoma With First-line Treatment Failure

Phase 2 Unknown

58 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT05097209 2023-03-23

Camrelizumab for the Treatment of Locally Advanced Nasopharyngeal Carcinoma

Phase 2 Unknown

200 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT05724355 2023-02-13

CDK4/6 Inhibitor Plus Camrelizumab for PD-1 Inhibitor Refractory R/M NPC

Phase 2 Unknown

32 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT05549466 2023-02-08

Targeted or Chemotherapy Combined With Immunotherapy Versus Chemotherapy for PD-1 Inhibitor Refractory R/M NPC

Phase 2 Unknown

84 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT05611463 2022-11-10

CHANCE

Phase 2 Unknown

25 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT03707509 2022-07-01

Phase III Study of Camrelizumab in Combination With Chemotherapy in Recurrent/Metastatic Nasopharyngeal Carcinoma

Phase 3 Unknown

263 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT04978012 2022-06-07

Fluzoparib and Camrelizumab in Treating Patients With R/M NPC That Progressed After First-line Chemotherapy

Phase 2 Unknown

48 enrolled

Head & Neck

Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms

NCT04143984 2022-04-29

Carbon-Ion Radiotherapy Plus Camrelizumab for Locally Recurrent Nasopharyngeal Carcinoma

Phase 2 Unknown

146 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT04539600 2021-08-19

Induction Chemotherapy Combined With Camrelizumab in Locoregionally Advanced Hypopharyngeal Cancer

Phase 2 Unknown

23 enrolled

Head & Neck

Hypopharyngeal Neoplasms

NCT04861467 2021-04-27

Camrelizumab as a Maintenance Therapy After Chemoradiation in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma

Phase 2 Unknown

155 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT04826679 2021-04-01

Neoadjuvant Camrelizumab in Combination With Cisplatin and Nab-paclitaxel in Resectable HNSCC

Phase 2 Unknown

53 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT04440917 2021-02-02

IMplus

Phase 2 Unknown

32 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT04612894 2020-11-03

Camrelizumab and Apatinib for Neoadjuvant Therapy in Thyroid Cancer

Phase 2 Unknown

31 enrolled

Head & Neck

Thyroid Neoplasms

NCT04547088 2020-09-14

Camrelizumab Combined With Apatinib in Patients With First-line Platinum-resistant Recurrent/Metastatic Nasopharyngeal Carcinoma

Phase 2 Unknown

27 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT04548271 2020-09-14

Camrelizumab Combined With Apatinib in Patients With PD-1 Antagonists Resistant Recurrent/Metastatic Nasopharyngeal Carcinoma

Phase 2 Unknown

25 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT04510818 2020-08-14

Combination of Metronomic Capecitabine With Camrelizumab for Treatment of Refractory Solid Tumor Trial (Cohort 2)

Phase 1 Unknown

20 enrolled

Head & Neck

Head and Neck Neoplasms

NCT04405154 2020-05-28

A Study of Concomitant Camrelizumab With Chemoradiation for Locally Advanced Head and Neck Cancer

Phase 2 Unknown

32 enrolled

Head & Neck

Carcinoma, Squamous Cell, Head and Neck Neoplasms

NCT04399785 2020-05-22

Phase II Study for Combination of Camrelizumab and SBRT in the First-line Treatment for R/M HNSCC

Phase 2 Unknown

34 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

Clinical Trials

DIPPER

Camrelizumab and Chemotherapy Combined With Endoscopic Surgery for Recurrent Nasopharyngeal Carcinoma

Advanced First-line Treatment of Short-term Postoperative Progression of Head and Neck Squamous Cell Carcinoma

A Phase II/III Trial to Evaluate the Efficacy and Safety of QL1706 in Patients With Nasopharyngeal Carcinoma

Induction Chemotherapy Combined With Immunotherapy for Locally Advanced Hypopharyngeal Carcinoma

Camrelizumab After Completion of Radiotherapy for Oligometastatic Nasopharyngeal Carcinoma

Apatinib and Camrelizumab in Recurrent or Metastatic Nasopharyngeal Carcinoma With First-line Treatment Failure

Camrelizumab for the Treatment of Locally Advanced Nasopharyngeal Carcinoma

CDK4/6 Inhibitor Plus Camrelizumab for PD-1 Inhibitor Refractory R/M NPC

Targeted or Chemotherapy Combined With Immunotherapy Versus Chemotherapy for PD-1 Inhibitor Refractory R/M NPC

CHANCE

Phase III Study of Camrelizumab in Combination With Chemotherapy in Recurrent/Metastatic Nasopharyngeal Carcinoma

Fluzoparib and Camrelizumab in Treating Patients With R/M NPC That Progressed After First-line Chemotherapy

Carbon-Ion Radiotherapy Plus Camrelizumab for Locally Recurrent Nasopharyngeal Carcinoma

Induction Chemotherapy Combined With Camrelizumab in Locoregionally Advanced Hypopharyngeal Cancer

Camrelizumab as a Maintenance Therapy After Chemoradiation in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma

Neoadjuvant Camrelizumab in Combination With Cisplatin and Nab-paclitaxel in Resectable HNSCC

IMplus

Camrelizumab and Apatinib for Neoadjuvant Therapy in Thyroid Cancer

Camrelizumab Combined With Apatinib in Patients With First-line Platinum-resistant Recurrent/Metastatic Nasopharyngeal Carcinoma

Camrelizumab Combined With Apatinib in Patients With PD-1 Antagonists Resistant Recurrent/Metastatic Nasopharyngeal Carcinoma

Combination of Metronomic Capecitabine With Camrelizumab for Treatment of Refractory Solid Tumor Trial (Cohort 2)

A Study of Concomitant Camrelizumab With Chemoradiation for Locally Advanced Head and Neck Cancer

Phase II Study for Combination of Camrelizumab and SBRT in the First-line Treatment for R/M HNSCC